Oncolytics director buys 100,000 ONCY shares

Q: What insider transactions did ONCY director Bernd R. Seizinger report?

Bernd R. Seizinger reported buying common shares of Oncolytics Biotech Inc. (ONCY) in two open-market transactions. He purchased 60,000 shares on February 11, 2026 and 40,000 shares on February 12, 2026 at prices below one dollar per share.

Q: How many Oncolytics Biotech (ONCY) shares does the director own after these trades?

After the reported trades, director Bernd R. Seizinger directly owns 566,991 common shares of Oncolytics Biotech Inc. (ONCY). This figure reflects the cumulative total following his February 11 and February 12, 2026 open-market purchase transactions disclosed in the Form 4.

Q: At what prices did the ONCY director buy common shares in February 2026?

Director Bernd R. Seizinger bought 60,000 ONCY common shares at $0.8265 per share on February 11, 2026. He then purchased an additional 40,000 common shares at $0.8466 per share on February 12, 2026 in open-market transactions.

Q: What does transaction code "P" mean in the ONCY Form 4 filing?

In this Form 4 for Oncolytics Biotech Inc. (ONCY), transaction code "P" indicates a purchase in the open market or private transaction. Both of director Bernd R. Seizinger’s February 2026 trades are classified under this purchase transaction code.

Q: Is the ownership reported by the ONCY director direct or indirect?

The filing shows that Bernd R. Seizinger’s holdings in Oncolytics Biotech Inc. (ONCY) are reported as direct ownership. The ownership code is listed as "D," and there is no separate nature of indirect beneficial ownership disclosed in the provided data.

Q: Which security class did the ONCY insider buy in these transactions?

The reported insider transactions involve Common Shares of Oncolytics Biotech Inc. (ONCY). On two consecutive days in February 2026, director Bernd R. Seizinger bought a total of 100,000 common shares in open-market purchases, as reflected in Table I of the filing.

Oncolytics Biotech director Bernd R. Seizinger bought additional common shares in two open-market transactions.

Accepted by SEC EDGAR 02/13/2026 - 07:00 AM EST

Filing Impact

(Moderate)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Oncolytics Biotech director Bernd R. Seizinger bought additional common shares in two open-market transactions. On February 11, 2026, he purchased 60,000 common shares at $0.8265 per share. On February 12, 2026, he bought another 40,000 common shares at $0.8466 per share.

After these transactions, Seizinger directly owns 566,991 common shares of Oncolytics Biotech Inc. The filing classifies both trades under transaction code "P," indicating purchases in the open market or private transactions.

Insider Trade Summary

Net Buyer: 100,000 shares

Net Buy 2 txns

Insider Seizinger Bernd R.

Role Director

Bought 100,000 shs ($83K)

Increase in Position 21.4%

Type	Security	Shares	Price	Value
Purchase	Common Shares	40,000	$0.8466	$34K
Purchase	Common Shares	60,000	$0.8265	$50K

Holdings After Transaction: Common Shares — 566,991 shares (Direct)

Holdings Before and After: Common Shares, 466,991 to 566,991 shares (Direct)

Other Insiders: 8 other insiders reported open-market purchases of this stock in the 30 days up to this filing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ONCY director Bernd R. Seizinger report?

Bernd R. Seizinger reported buying common shares of Oncolytics Biotech Inc. (ONCY) in two open-market transactions. He purchased 60,000 shares on February 11, 2026 and 40,000 shares on February 12, 2026 at prices below one dollar per share.

How many Oncolytics Biotech (ONCY) shares does the director own after these trades?

After the reported trades, director Bernd R. Seizinger directly owns 566,991 common shares of Oncolytics Biotech Inc. (ONCY). This figure reflects the cumulative total following his February 11 and February 12, 2026 open-market purchase transactions disclosed in the Form 4.

At what prices did the ONCY director buy common shares in February 2026?

Director Bernd R. Seizinger bought 60,000 ONCY common shares at $0.8265 per share on February 11, 2026. He then purchased an additional 40,000 common shares at $0.8466 per share on February 12, 2026 in open-market transactions.

What does transaction code "P" mean in the ONCY Form 4 filing?

In this Form 4 for Oncolytics Biotech Inc. (ONCY), transaction code "P" indicates a purchase in the open market or private transaction. Both of director Bernd R. Seizinger’s February 2026 trades are classified under this purchase transaction code.

Is the ownership reported by the ONCY director direct or indirect?

The filing shows that Bernd R. Seizinger’s holdings in Oncolytics Biotech Inc. (ONCY) are reported as direct ownership. The ownership code is listed as "D," and there is no separate nature of indirect beneficial ownership disclosed in the provided data.

Which security class did the ONCY insider buy in these transactions?

The reported insider transactions involve Common Shares of Oncolytics Biotech Inc. (ONCY). On two consecutive days in February 2026, director Bernd R. Seizinger bought a total of 100,000 common shares in open-market purchases, as reflected in Table I of the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Seizinger Bernd R.

(Last)

(First)

(Middle)

C/O ONCOLYTICS BIOTECH INC.

4350 EXECUTIVE DRIVE, SUITE 325

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	02/11/2026		P		60,000	A	$0.8265	526,991	D
Common Shares	02/12/2026		P		40,000	A	$0.8466	566,991	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Kirk Look, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR